This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Mina Chung, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00599118
First received: January 10, 2008
Last updated: July 21, 2017
Last verified: July 2017
  Purpose
The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Mina Chung, The Cleveland Clinic:

Primary Outcome Measures:
  • Genetic variants associated with atrial fibrillation [ Time Frame: Baseline ]
    Genome-wide association study of atrial fibrillation


Biospecimen Retention:   Samples With DNA
plasma, serum, buffy coat, DNA

Estimated Enrollment: 1300
Actual Study Start Date: August 2005
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
atrial fibrillation
Atrial fibrillation
Control
Control subjects with no atrial fibrillation

Detailed Description:
Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects with atrial fibrillation
Criteria

Inclusion Criteria for Atrial Fibrillation group:

  • Male or female at least 18 years old
  • Subjects with a history of or current Atrial Fibrillation
  • Subjects able to give informed consent Exclusion Criteria for Atrial Fibrillation group: no history of atrial fibrillation

Inclusion Criteria for Controls:

  • Male or female at least 18 years old
  • Subjects with no history of Atrial Fibrillation
  • Subjects able to give informed consent Exclusion Criteria for controls: History of atrial fibrillation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599118

Locations
United States, Ohio
Cleveland Clinical Foundation
Cleveland, Ohio, United States, 44145
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: Mina K Chung, MD The Cleveland Clinic
  More Information

Responsible Party: Mina Chung, Principal Investigator, The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT00599118     History of Changes
Other Study ID Numbers: 8271
Study First Received: January 10, 2008
Last Updated: July 21, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mina Chung, The Cleveland Clinic:
Atrial Fibrillation
Genetics

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on September 19, 2017